Legal Scrutiny Follows Rezolute's Clinical Trial Setback

Law firm investigates Rezolute after sunRIZE trial misses endpoints, triggering stock drop. Company has $132.9M cash, awaits FDA meeting and upLIFT data in 2026.

Biopharmaceutical firm Rezolute, Inc. is now facing legal scrutiny following the disappointing outcome of a key clinical trial. The US law firm Faruqi & Faruqi has initiated an investigation into potential claims related to the sunRIZE Phase 3 study results. This development raises questions about the future trajectory of the company's lead drug candidate, Ersodetug, and the potential impact of this legal pressure.

Financial Position and Upcoming Catalysts

The company's financial standing was detailed in its recent second-quarter fiscal 2026 report. Rezolute posted a net loss of $22.8 million for the period. Its liquidity position, however, remains secured for the near term, with cash, cash equivalents, and marketable securities totaling approximately $132.9 million as of the end of December.

The coming months are pivotal. A critical meeting with the U.S. Food and Drug Administration (FDA) is scheduled for the current first quarter of fiscal 2026. This discussion will determine the regulatory path forward for the Ersodetug program. Concurrently, the upLIFT study, investigating the drug for tumor-associated hyperinsulinism, continues. Initial topline data from this separate trial are anticipated in the second half of calendar year 2026.

Disappointing Data Triggers Probe and Stock Decline

The legal investigation centers on data released by the company in December. The sunRIZE trial, which evaluated Ersodetug for the treatment of congenital hyperinsulinism (HI), failed to meet both its primary and key secondary endpoints. Even at the highest dose, the reduction in hypoglycemic events was not statistically significant compared to a placebo.

The announcement of these results triggered a substantial decline in the company's share price at the time. Management has emphasized that despite missing the clinical endpoints, pharmacological activity was observed and target drug concentrations were achieved. They also pointed to certain biomarker and continuous glucose monitoring (CGM) signals. All participants who completed the trial subsequently enrolled in an open-label extension phase.